Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Duke University
- Target Recruit Count
- 38
- Registration Number
- NCT02057939
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT02034552
Enzalutamide + External Beam Rt For Prostate
- Conditions
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 64
- Registration Number
- NCT02028988
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 25
- Registration Number
- NCT02023463
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 88
- Registration Number
- NCT02012296
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Cancer Care Specialists of Central Illinois (Decatur) /Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 247
- Registration Number
- NCT02007512
- Locations
- 🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Investigational Drug Services, Indianapolis, Indiana, United States
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1402
- Registration Number
- NCT02003924
- Locations
- 🇫🇷
CHRU de Brest, Brest, France
🇺🇸Chesapeake Urology Research Associates, Baltimore, Maryland, United States
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 509
- Registration Number
- NCT01995513
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇧🇪Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT01990196
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Dendreon
- Target Recruit Count
- 52
- Registration Number
- NCT01981122
- Locations
- 🇺🇸
Urology of Virginia, Virginia Beach, Virginia, United States
🇺🇸Northwest Medical Specialties, Rainier Physicians, Tacoma, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.